tbuckley/cabot-search huggingface dataset:
Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis
Authors: Binu V. John, Yangyang Deng, Kaley B. Schwartz, Tamar H. Taddei, David E. Kaplan, Paul Martin, Hann‐Hsiang Chao, Bassam Dahman
Journal: Hepatology (2022)

Abstract Background and Aims Patients develop breakthrough COVID‐19 infection despite vaccination. The aim of this study was to identify outcomes in patients with cirrhosis who developed postvaccination COVID‐19. Methods We performed a retrospective cohort study among US veterans with cirrhosis and postvaccination or unvaccinated COVID‐19. Patients were considered fully vaccinated if COVID‐19 was diagnosed 14 days after the second dose of either the Pfizer BNT162b2, the Moderna 1273‐mRNA, or the single‐dose Janssen Ad.26.COV2.S vaccines and partially vaccinated if COVID‐19 was diagnosed 7 days after the first dose of any vaccine but prior to full vaccination. We investigated the association of postvaccination COVID‐19 with mortality. Results We identified 3242 unvaccinated and 254 postvaccination COVID‐19 patients with cirrhosis (82 after full and 172 after partial vaccination). In a multivariable analysis of a 1:2 propensity‐matched cohort including vaccinated ( n = 254) and unvaccinated ( n = 508) participants, postvaccination COVID‐19 was associated with reduced risk of death (adjusted HR [aHR], 0.21; 95% CI, 0.11–0.42). The reduction was observed after both full (aHR, 0.22; 95% CI, 0.08–0.63) and partial (aHR, 0.19; 95% CI, 0.07–0.54) vaccination, following the 1273‐mRNA (aHR, 0.12; 95% CI 0.04–0.37) and BNT162b2 (aHR, 0.27; 95% CI, 0.10–0.71) vaccines and among patients with compensated (aHR, 0.19; 95% CI, 0.08–0.45) and decompensated (aHR, 0.27; 95% CI, 0.08–0.90) cirrhosis. Findings were consistent in a sensitivity analysis restricted to participants who developed COVID‐19 after vaccine availability. Conclusions Though patients with cirrhosis can develop breakthrough COVID‐19 after full or partial vaccination, these infections are associated with reduced mortality.
Genetic influences on left ventricular diastolic filling parameters in american indians: The strong heart study Jonathan N. Bella, Richard B. Devereux, Kari North, Mary J. Roman, Jennifer E. Liu, Vittorio Palmieri, Thomas K. Welty, Elisa T. Lee, Richard R. Fabsitz, Barbara V. Howard, Jean W. MacCluer. Weill Medical College of Cornell University, New York, NY, Southwest Foundation for Biomedical Research, San Antonio, TX
Journal: Journal of the American College of Cardiology (2001)
US Medical School Finances
Authors: H. Paul Jolly
Journal: JAMA (1982)

The 22nd annual review of medical school finances has again been prepared by the Division of Operational Studies of the Association of American Medical Colleges (AAMC). Each year, to the fullest extent possible, medical schools have adhered to uniform guidelines and instructions in providing revenue and expenditure data requested in the Annual Medical School Questionnaire of the Liaison Committee on Medical Education (LCME). The scope and format of the questionnaire have been revised from time to time in the past two decades, but these revisions have not altered the definitions for the major items to be reported. Uniform definitions were established for the first time for the 1958-1959 survey; the resulting data were published in the 60th Annual Report on Medical Education. Expansion and changes in the questionnaire have been necessary because of the need for more information to describe the ever-broadening activities and responsibilities of the nation's medical schools.
Comparison of left atrial dimensions by transthoracic and transesophageal echocardiography Matthew Block, Lisa Hourigan, Wayne H. Bellows, John Reeves, III, Joseph L. Romson, Michael Tran, Darwin Pastor, Nelson Schiller, Jacqueline M. Leung. California Pacific Medical Center, San Francisco, CA, University of California, San Francisco, San Francisco, CA
Journal: Journal of the American College of Cardiology (2001)
Data Sharing
Authors: Dan L. Longo, Jeffrey M. Drazen
Journal: New England Journal of Medicine (2016)

The aerial view of the concept of data sharing is beautiful. What could be better than having high-quality information carefully reexamined for the possibility that new nuggets of useful data are lying there, previously unseen? The potential for leveraging existing results for even more benefit pays appropriate increased tribute to the patients who put themselves at risk to generate the data. The moral imperative to honor their collective sacrifice is the trump card that takes this trick. However, many of us who have actually conducted clinical research, managed clinical studies and data collection and analysis, and curated data sets have . . .
Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial
Authors: Anthony C. Nichols, Julie Theurer, Eitan Prisman, Nancy Read, Eric Berthelet, Eric Tran, Kevin Fung, John R. de Almeida, Andrew Bayley, David P. Goldstein, Michael Hier, Khalil Sultanem, Keith Richardson, Alex Mlynarek, Suren Krishnan, Hien Le, John Yoo, S. Danielle MacNeil, Eric Winquist, J. Alex Hammond, Varagur Venkatesan, Sara Kuruvilla, Andrew Warner, Sylvia Mitchell, Jeff Chen, Martin Corsten, Stephanie Johnson-Obaseki, Michael Odell, Christina Parker, Bret Wehrli, Keith Kwan, David A. Palma
Journal: Journal of Clinical Oncology (2022)

The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has risen rapidly, because of an epidemic of human papillomavirus infection. The optimal management of early-stage OPSCC with surgery or radiation continues to be a clinical controversy. Long-term randomized data comparing these paradigms are lacking.We randomly assigned patients with T1-T2, N0-2 (≤ 4 cm) OPSCC to radiotherapy (RT) (with chemotherapy if N1-2) versus transoral robotic surgery plus neck dissection (TORS + ND) (with or without adjuvant therapy). The primary end point was swallowing quality of life (QOL) at 1-year using the MD Anderson Dysphagia Inventory. Secondary end points included adverse events, other QOL outcomes, overall survival, and progression-free survival. All analyses were intention-to-treat. Herein, we present long-term outcomes from the trial.Sixty-eight patients were randomly assigned (n = 34 per arm) between August 10, 2012, and June 9, 2017. Median follow-up was 45 months. Longitudinal MD Anderson Dysphagia Inventory analyses demonstrated statistical superiority of RT arm over time (P = .049), although the differences beyond 1 year were of smaller magnitude than at the 1-year timepoint (year 2: 86.0 ± 13.5 in the RT arm v 84.8 ± 12.5 in the TORS + ND arm, P = .74; year 3: 88.9 ± 11.3 v 83.3 ± 13.9, P = .12). These differences did not meet the threshold to qualify as a clinically meaningful change at any timepoint. Certain differences in QOL concerns including more pain and dental concerns in the TORS + ND arm seen at 1 year resolved at 2 and 3 years; however, TORS patients started to use more nutritional supplements at 3 years (P = .015). Dry mouth scores were higher in RT patients over time (P = .041).On longitudinal analysis, the swallowing QOL difference between primary RT and TORS + ND approaches persists but decreases over time. Patients with OPSCC should be informed about the pros and cons of both treatment options (ClinicalTrials.gov identifier: NCT01590355).
The Propaganda for Reform
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: The SPAN-CHF trial Carey D. Kimmelstiel, Daniel Levine, Kathleen Perry, Ayan Patel, Ara Sadaniantz, Noreen Gorham, Peggy Cunnie, Lynn Duggan, Linda Cotter, Kenneth LaBresh, David Brill, William Rand, James Udelson, Beverly Lorell, Marvin A. Konstam. New England Medical Center, Boston, MA
Journal: Journal of the American College of Cardiology (2001)
JAMA Reference Directories
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Management of Atrial Fibrillation in Patients 75 Years and Older
Authors: Annabelle Santos Volgman, Gatha Nair, Radmila Lyubarova, Faisal M. Merchant, Pamela Mason, Anne B. Curtis, Nanette K. Wenger, Neelum T. Aggarwal, James N. Kirkpatrick, Emelia J. Benjamin
Journal: Journal of the American College of Cardiology (2022)
LINCS: L-NMMA in cardiogenic shock: Preliminary results from a prospective randomized study Gad Cotter, Edo Kaluski, Olga Milovanov, Alex Blatt, Ahmed Salah, Rikardo Krakover, Zvi Vered. Assaf-Harofeh Medical Center, Zerifin, Israel
Journal: Journal of the American College of Cardiology (2001)
Circulating tumor DNA-based molecular residual disease detection and recurrence monitoring in patients with advanced or metastatic anal squamous cell carcinoma.
Authors: Georges Azzi, Mehrad Tavallai, Gregory P. Botta, Mohamedtaki Abdulaziz Tejani, Diana L. Hanna, Adham Adel Jurdi, Griffin Budde, Shifra Krinshpun, Minu Maninder, Vasily N. Aushev, Perry Olshan, Paul R. Billings, Alexey Aleshin, Pashtoon Murtaza Kasi
Journal: Journal of Clinical Oncology (2022)

6 Background: For patients with anal squamous cell carcinoma (ASCC), the current standard of care involves curative-intent definitive chemoradiation. For those that recur locally, salvage surgery maybe a consideration. ASCC, however, still lacks a non-invasive blood-based biomarker, which can be of value in this patient population for monitoring recurrence and/or response to immunotherapy later. Circulating tumor DNA (ctDNA) is a promising non-invasive tool to assess molecular residual disease (MRD) and recurrence in ASCC. Here, we evaluated real-world utility of ctDNA status to identify MRD and recurrence in ASCC patients across all stages. Methods: This is a retrospective analysis of patients with any stage ASCC receiving SOC or/and immunotherapy with immune checkpoint inhibitors. A personalized tumor-informed PCR/NGS-based assay (Signatera) was used for ctDNA detection, in the pre/on/post-treatment and surveillance setting. Results: In this study, plasma samples (n=105) were collected from 25 ASCC patients (13 females, 12 males; median age 66 years) at various timepoints for a median follow-up of 315 days (range: 59-1717), post-diagnosis; 12 patients were HPV-positive, 1 patient was HPV-negative, and 12 had unknown HPV status; 88% (22/25) of the patients had serial timepoints (≥2) available. ctDNA-positivity rates, test results, and ctDNA quantification by stage are summarized in Table. The quantitated ctDNA values (mean tumor molecules (MTM)/mL) increased in concordance with the stage of the disease, with values trending higher in stage III and IV. In addition, complete clinical outcome information was available for 22/25 patients at the time of releasing this data. Of the 96 plasma samples drawn from these patients, 68 (70%) were in the surveillance setting (post-definitive therapy). No recurrences were observed among 15 patients who cleared ctDNA on treatment and/or tested negative post-treatment, whereas, 6/7 ctDNA-positive patients were confirmed to have disease recurrence and 1 was pending confirmatory imaging. This often predated recurrence on scans. Conclusions: Measuring and monitoring MRD in patients with ASCC is feasible and has the potential to impact clinical decision making. Our study is the first to set the benchmark for the feasibility of using a tumor-informed assay in ASCC. Larger prospective studies are needed to explore the clinical utility of ctDNA status to guide disease surveillance and management of ASCC.[Table: see text]
Vaccine equity . . . and other stories
Journal: BMJ (2022)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Vaccine equity . . . and other stories Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
THE ASSOCIATION OF FRAILTY WITH MORTALITY IN HIGH RISK PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT: AN ANALYSIS OF THE PARTNER II B TRANSFEMORAL COHORT
Authors: Alan Zajarias, Hersh Maniar, Suzanne Arnold, Nishath Quader, David Cohen, Spencer Melby, Maria Alu, Girma Ayele, Brian Lindman, John Lasala, Raj Makkar, Vasilis Babaliaros, Howard Herrmann, Michael Mack, Martin Leon, Philip Green
Journal: Journal of the American College of Cardiology (2016)
Effects of vitamin E
Authors: A. R. Gaby
Journal: JAMA (1982)

<h3>To the Editor.—</h3> I have read the account in MEDICAL NEWS by Mr William A. Check, on "Carotid Endarterectomy's Value Still Uncertain" (1982; 247:1802). This was a report of a study that was done with my colleagues, Drs B. A. Sandok and T. M. Sundt, Jr. Although there are always minor points that might be raised after a reporter presents his understanding of a scientific presentation, on this occasion Mr Check has included one statement that may be highly misleading to readers. In referring to our patients who had carotid endarterectomy, he noted that, "None of the stenoses were complicated by ulcerative plaque." That statement was not made in the presentation or in his interview later. This is a critical point, as a high percentage of severe stenoses of the common and internal carotid arteries are associated with ulceration of the plaque, whether or not it is evident on angiographic
A polymorphism in the promoter of the CD14 receptor gene is associated with circulating soluble CD14 levels and with an enhanced pro-inflammatory response in patients with unstable angina Giovanna Liuzzo, Dominick J. Angiolillo, Pier F. Pignatti, Chiara Stranieri, Matteo Santamaria, Vittoria Rizzello, Francesca Ginnetti, Antonio Buffon, Luigi M. Biasucci, Attilio Maseri. Catholic University, Rome, Italy
Journal: Journal of the American College of Cardiology (2001)
Surgical Treatment of Diseases of the Brain.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Measures Against Dispensary Abuse at Paris
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"Vindex" AND THE JUDICIAL COUNCIL
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New knowledge about nicotine effects
Authors: W. A. Check
Journal: JAMA (1982)

Remember the cigarette advertisements of the 1940s: "Reach for a Lucky instead of a sweet" and "Have a Camel with your meal and after it—they satisfy"? Well, recent research suggests that those ads were accurate. It appears that cigarettes may reduce the desire for sweets and help some people to achieve greater satisfaction from their meals. And the responsible ingredient seems to be nicotine. In fact, a wealth of recent evidence indicates that nicotine in cigarettes is responsible for a host of physiological and psychological effects and that these alterations in metabolism and mood are a major reason why people smoke—and find it so hard to stop smoking. This research is buttressed by the therapeutic use of nicotine-containing gum to aid in smoking cessation. In one soon-to-be-published placebo-controlled trial, use of the gum doubled quit rates. "In the 1950s people talked about cigarette smoking as a psychosocial habit," notes Lynn
Lamin A/C gene mutations in families with dilated cardiomyopathy, conduction system defects, and skeletal muscle disease Matthew R. G. Taylor, Gary L. Brodsky, Francesco Muntoni, Gianfranco Sinagra, Andrea Di Lenarda, Misi Robinson, Pamela Fain, Luisa Mestroni. University of Colorado Health Sciences Center: Cardiovascular Institute, Denver, CO, Imperial Colege School of Medicine, London, United Kingdom
Journal: Journal of the American College of Cardiology (2001)
2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia
Authors: Richard L. Page, José A. Joglar, Mary A. Caldwell, Hugh Calkins, Jamie B. Conti, Barbara J. Deal, N.A. Mark Estes, Michael E. Field, Zachary D. Goldberger, Stephen C. Hammill, Julia H. Indik, Bruce D. Lindsay, Brian Olshansky, Andrea M. Russo, Win-Kuang Shen, Cynthia M. Tracy, Sana M. Al-Khatib
Journal: Journal of the American College of Cardiology (2015)
Manuscripts Approved for JNCI, November 1 to December 1, 1964
Journal: JNCI Journal of the National Cancer Institute (1965)

Manuscripts Approved for JNCI, November 1 to December 1, 1964 JNCI: Journal of the National Cancer Institute, Volume 34, Issue 1, January 1965, Pages 155–156, https://doi.org/10.1093/jnci/34.1.155-a Published: 01 January 1965
Questions and Answers
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Masci PG, Ganame J, Strata E, Desmet W, Aquaro GD, Dymarkowski S, Valenti V, Janssens S, Lombardi M, Van de Werf F, L'Abbate A, Bogaert J. Myocardial Salvage by CMR Correlates With LV Remodeling and Early ST-Segment Resolution in Acute Myocardial Infarction. J Am Coll Cardiol Img 2010;3:45–51
Journal: JACC. Cardiovascular imaging (2010)